Clinical trial
Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer
NCT00003453 · Burzynski Research Institute, Other · Terminated
Key facts
| NCT number | NCT00003453 |
|---|---|
| Title | Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer |
| Official title | Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Adrenal Gland |
| Lead sponsor | Burzynski Research Institute, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage IV Adrenocortical Carcinoma |
| Intervention type | Drug |
| Interventions | Antineoplaston therapy (Atengenal + Astugenal) |
| Enrollment | 6 |
| Start date | Aug 21, 1996 |
| Primary completion | Jul 5, 2011 |
| Completion | Jul 5, 2011 |
| First posted | Jan 27, 2003 |
| Last update posted | May 9, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: